iii期非小细胞肺癌周剂量多西他赛同步适形放疗

《iii期非小细胞肺癌周剂量多西他赛同步适形放疗》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、中文摘要⋯⋯·英文摘要·符号说明目录前言⋯⋯资料与方法结果⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯-·29讨论⋯”结论⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯附图⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯4l参考文献⋯⋯⋯⋯⋯·综述⋯⋯⋯⋯致谢⋯⋯⋯⋯⋯⋯⋯⋯”⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·43攻读硕士期间发表的论文⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·55原创性声明⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·surrou

2、nding90％～95％PTv．90％PrVacceptingmini如umabsorbeddose．TheradiationdoseforstageT1～2was60GyandstageT3"～4Was64---66Gy．SupraclavicularlymphaticmetastasisWastreatedwithCobalt-60gammaraysand12MeVelectronrays，thedosesametoprimarytumors．3Othertreatments：Bloodro

3、utineexaminationwasmonitoredeveryweek，hepatorenalfunctionandwaterelectrolytemetabolismmonitoredevery2weeks．Whenleukocyte_<2．0xl09，granulocytecolony-stimulatingfactor(G-CSF)wasused．Thedosageis599／kg／dwithsubcutaneousinjection．Thepatientsexperienced冱gr

4、ademyelosuppressionduringinductionchemotherapyshouldacceptG-CSFprophylacticly，24一-72hoursafterchemotherapy，untilgranuloeytefrommininlll／／1leveltonormallevelorleukocyte>i0．Oxl09．Whenthepatientspresentedwithdysfunctionofliver,diammoniumglycyrrhizinatew

5、asinjected,untilaminopherasetonormallevel．Whenpresentedradiationpneumonitisconcomitantwithfever，sputumcultureplusdrugsensitivitytestshouldbecarriedouttoselectreasonableantibiotic，combined州thcoughsuppressantandexpectorant．Whenappearingradiationesophag

6、itis，mucosalanaestheticandglucocorficoidshouldbeused．Whenleukocytedeclining，generaldmgshouldbeused，suchasdiyushengbaitablet，leucogen，batil01．Results1Completedstatus：Allpatientsrceivedthewholetreatmentcourse．ThereWasnoonetoterminateradiotherapy．ThereW

7、asonly10patientsnotfinishing6cyclesweeklydocetaxolbecauseoftransientmyelosuppression，radiationpneumonifisandradiationesophagitis．ThemedianradiotherapytimeofdurationWas43clays(土2days．)，andmedianradiotherapydose62Gy(60Gy--。66Gy)．2Evaluationoftherapeuti

8、cefficiency：Completeremission13cases(13．1％)，partialremission35cases(35．4％)，stabledisease24cases(24．2％)，progressdisease17cases(17．2％)，death7cases(7．1％)，losstofollow-up3cases(3．0％)．Theresponserate(CR+PR)Was48．5％，diseasecontrolrate(CR+PR+SD)Was72．7％．3Su